MSc Cancer Immunotherapy
Why choose Herts?
Teaching Excellence: You will be taught by Internationally renowned researchers who support with research projects in Cancer Immunotherapy.
Employment Prospects: Graduates work as research scientists, scientific officers, and senior managers for organisations including Roche, Merck, and Astra Zeneca.
Sector-led Course Content: Explore our research interests of the Bioscience Research Group covering topics such as Adoptive T cell therapy, tumour-associated macrophages, NK cells, and monoclonal antibodies in cancer therapy.
Professional Accreditations
Subject to validation, this course will be accredited by the Royal Society for Biology Accreditation.
About the course
The aim of the MSc in Cancer Immunotherapy is through an understanding of the numerous ways in which cancers and the immune system interact, to learn how cancer immunotherapies are developed. The utilisation of the immune system in cancer therapy has been a long standing goal in the field. The course will provide a thorough understanding of immune effector mechanisms and of cancer biology and the personal skills the students will develop, through problem-based learning and self-directed learning.
Alternatively, consider taking our other MSc Cancer Immunotherapy routes:
Why choose this course?
- 92% overall satisfaction for Medicine and Dentistry in the Postgraduate Taught Experience Survey (PTES, 2024)
- You’ll be taught by our expert staff and innovative speakers from the biopharmaceutical industry
- Our modern Science Building provides excellent facilities for laboratory experiments, including DNA and genomic analysis eg QPCR, protein and proteomic science (eg MALDI-ToF), cell culture and Enzyme-based assays, isolated tissue studies and immunohistochemistry
- When you graduate, you’ll be equipped to work in a broad range of fields including medical or pharmaceutical research and development, clinical trials, public health and epidemiology, academia research, medical writing and science journalism, education, or patent law
- We adopt a blended learning approach to teaching, focussing on problem-based scenarios so you can develop strong critical analysis skills. You’ll benefit from exposure to practical techniques and guaranteed laboratory-based research projects
What will I study?
You’ll benefit from the research interests of the Bioscience Research Group. These include studies of the tumour microenvironment and communication with infiltrating immune cells, the methods tumours employ to diminish the effectivity of immune effector mechanisms and how tumours communicate using extracellular vesicles with pre-metastatic sites. We’ll cover topics such as adoptive T cell therapy, tumour-associated macrophages, NK cells, monoclonal antibodies in cancer therapy, vaccines, microbial cancer therapies and immune checkpoint blockade.
Teaching will be delivered through lectures, tutorials and practical classes. You’ll immerse yourself in a research project which utilises problem-based and self-directed learning. You’ll explore case studies to gain a strong critical understanding. Through your research projects, carried out in our innovative Science Building and supervised by world-leading researchers, you’ll be trained in data collection, analysis and its interpretation. You’ll also benefit from expert external speakers from the biopharmaceutical industry.
Key staff
Dr Madhu Goyal
Programme Leader
Find out more about Dr Madhu Goyal
Dr Shoib Siddiqui
Deputy Programme Leader
Further course information
Course fact sheets | |
---|---|
MSc Cancer Immunotherapy (Revised 2024) | Download |
Programme specifications | |
---|---|
MSc Cancer Immunotherapy (Revised 2024) | Download |
Additional information | |
---|---|
Sandwich placement or study abroad year |
n/a |
Applications open to international and EU students |
Yes |